Insight Molecular Diagnostics (IMDX) EBT Margin (2020 - 2026)
Insight Molecular Diagnostics (IMDX) posted EBT Margin of 35131.25% for Q1 2026, down 1583.83% sequentially from 2086.39% in Q4 2025, and down 3476539.0% YoY from N/an in Q1 2025.
Insight Molecular Diagnostics (IMDX) EBT Margin (2020 - 2026) Analysis & Trends
Insight Molecular Diagnostics has reported EBT Margin for 7 years, with the latest figure at 35131.25% in Q1 2026.
- Quarterly EBT Margin fell 3476539.0% year-over-year to 35131.25% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 2621.34% (down 116915.0% YoY) and the FY2025 annual result came in at 1471.29%, up 519947.0% from the prior year.
- EBT Margin declined to 35131.25% in Q1 2026 per IMDX's latest filing, from 2086.39% in the prior quarter.
- Over five years, EBT Margin peaked at 2006.4% in Q1 2023 and troughed at 35131.25% in Q1 2026.
- A 5-year average of 4274.16% and a median of 2086.39% in 2025 frame the typical range for EBT Margin.
- The sharpest annual moves came in 2025 and 2026: EBT Margin soared 482108 bps in 2025, then slumped 3476539 bps in 2026.
- Over 5 years, EBT Margin stood at 301.25% in 2022, then plunged by 1591 bps to 5092.99% in 2023, then surged by 55 bps to 2281.7% in 2024, then grew by 9 bps to 2086.39% in 2025, then slumped by 1584 bps to 35131.25% in 2026.
- According to Business Quant data, EBT Margin over the past three periods registered 35131.25%, 2086.39%, and 2943.85% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 213.88 Bn | 209.81 Bn | 8.34 Bn | 16.04% |
| 2 | Danaher | 140.65 Bn | 136.30 Bn | 3.61 Bn | 17.21% |
| 3 | Idexx Laboratories | 46.02 Bn | 45.83 Bn | 779.09 Mn | 34.29% |
| 4 | Agilent Technologies | 39.85 Bn | 38.05 Bn | 990.00 Mn | 22.23% |
| 5 | Iqvia Holdings | 39.20 Bn | 37.12 Bn | 1.44 Bn | 6.89% |
| 6 | Natera | 38.80 Bn | 37.70 Bn | 696.04 Mn | -12.17% |
| 7 | Illumina | 30.11 Bn | 28.94 Bn | 770.00 Mn | 22.43% |
| 8 | Mettler Toledo International | 28.66 Bn | 28.61 Bn | 650.22 Mn | 28.17% |
| 9 | Quest Diagnostics | 26.24 Bn | 25.61 Bn | 1.03 Bn | 13.54% |
| 10 | Insight Molecular Diagnostics | 172.42 Mn | 143.49 Mn | 15,000.00 | -35,131.25% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -35,131.25% |
| Dec 31, 2025 | -2,086.39% |
| Sep 30, 2025 | -2,943.85% |
| Jun 30, 2025 | -1,627.41% |
| Mar 31, 2025 | -365.86% |
| Dec 31, 2024 | -2,281.70% |
| Sep 30, 2024 | -7,726.09% |
| Jun 30, 2024 | -4,995.19% |
| Mar 31, 2024 | -5,186.93% |
| Dec 31, 2023 | -5,092.99% |
| Sep 30, 2023 | -1,512.59% |
| Jun 30, 2023 | -1,799.78% |
| Mar 31, 2023 | 2,006.40% |
| Dec 31, 2022 | -301.25% |
| Sep 30, 2022 | -2,713.43% |
| Jun 30, 2022 | -575.53% |
| Mar 31, 2022 | -326.92% |
| Dec 31, 2021 | -997.16% |
| Sep 30, 2021 | -1,402.44% |
| Jun 30, 2021 | -605.27% |